This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Mylan, Lupin Collaborate for the Proposed Biosimilar Enbrel
by Zacks Equity Research
Mylan (MYL) enters a partnership with Lupin Limited to commercialize a biosimilar of blockbuster drug Enbrel on approval.
Puma Biotechnology's Shares Rise on Positive CHMP Trend Vote
by Zacks Equity Research
Puma Biotechnology's (PBYI) marketing application seeking approval for neratinib in breast cancer gets positive CHMP trend vote, following a negative opinion in February.
AbbVie (ABBV), Calico Extend R&D Deal, to Invest $500M Each
by Zacks Equity Research
AbbVie (ABBV) and Alphabet backed biotech Calico Life Sciences extend their 2014 R&D collaboration by investing another $500 million each to develop candidates to treat age-related diseases.
AbbVie's (ABBV) Imbruvica sNDA Gets Priority Review From FDA
by Zacks Equity Research
The FDA grants a priority review to AbbVie's (ABBV) lymphoma drug Imbruvica sNDA, for the treatment of Waldenstr??m's macroglobulinemia (WM).
Roche's (RHHBY) Flu Candidate Gets Priority Review by the FDA
by Zacks Equity Research
Roche's (RHHBY) member Genentech announces that the FDA has accepted a new drug application (NDA) and granted priority review to its baloxavir marboxil to treat patients suffering from influenza A and influenza B.
Roche's (RHHBY) Study on Tecentriq for Lung Cancer Positive
by Zacks Equity Research
Roche's (RHHBY) phase III study on immuno-oncology drug, Tecentriq, for the treatment of small cell lung cancer meet its co-primary endpoints.
Bristol-Myers' BLA for Opdivo Label Expansion Accepted by FDA
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announces that the FDA accepts its supplemental Biologics License Application (sBLA) for the label expansion of its blockbuster immuno-oncology drug Opdivo.
Pharma Stock Roundup: PTCT Unveils Promising Data, RHHBY to Acquire Rest of FMI
by Zacks Equity Research
Roche (RHHBY) will buy the remaining stake in Foundation Medicine for $2.4 billion. PTC Therapeutics (PTCT) presents encouraging preliminary data from an early-stage study in spinal muscular atrophy.
TESARO (TSRO) Stock Up on Rumors of Buyout Offer From Roche
by Zacks Equity Research
Shares of TESARO (TSRO) rise on speculation of an acquisition bid from Roche.
Will Roche's (RHHBY) Acquisition Spree Revive the Top Line?
by Zacks Equity Research
Roche (RHHBY) is looking to boost its portfolio with some strategic acquisitions and we expect further activities on this front.
Roche to Buy Rest of Foundation Medicine for $2.4 billion
by Zacks Equity Research
Roche inks a deal with Foundation Medicine to acquire the remaining shares of Foundation Medicine, not already owned by it for a total consideration of $2.4 billion.
PTC Therapeutics' Spinal Muscular Atrophy Study Successful
by Zacks Equity Research
PTC Therapeutics' (PTCT) shares rally on encouraging preliminary data from a pivotal study evaluating risdiplam in babies with spinal muscular atrophy.
ImmunoGen's Lead Candidate Gets Fast Track for Ovarian Cancer
by Zacks Equity Research
With ImmunoGen's (IMGN) lead pipeline candidate, mirvetuximab soravtansine getting Fast Track designation in the United States, its development and review are likely to get expedited.
Bristol-Myers Posts Data on Empliciti, China Approves Opdivo
by Zacks Equity Research
Bristol-Myers (BMY) announces positive results on oncology drug Empliciti. The company's blockbuster drug, Opdivo, was also approved in China for lung cancer.
Roche Announces Positive Data on Gazyva and MS Drug Ocrevus
by Zacks Equity Research
Roche (RHHBY) announced positive long-term data on leukemia drug Gazyva and MS drug Ocrevus.
Pharma Stock Roundup: LLY/AZN Alzheimer's Drug Fails, MRK's Keytruda Wins Approvals
by Zacks Equity Research
Eli Lilly (LLY)/AstraZeneca (AZN) discontinue two late-stage studies on Alzheimer's disease candidate, lanabecestat. Merck's Keytruda gets FDA nod for two new indications.
Roche's (RHHBY) Avastin Gets Label Expansion Approval by FDA
by Zacks Equity Research
Roche (RHHBY) announced that the FDA has approved the label expansion for its oncology drug Avastin in combination with chemotherapy, for the treatment of women with advanced ovarian cancer following initial surgical resection.
Abbvie/Roche's Leukemia Drugs Combination Gets FDA Approval
by Zacks Equity Research
AbbVie (ABBV) and Roche's (RHHBY) cancer drugs, Venclexta and Rituxan receive approval for combination use in second-line chronic lymphocytic leukemia.
The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AbbVie
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AbbVie
Pharma Stock Roundup: MRK Impresses at ASCO, LLY Gets FDA Nod for Olumiant
by Zacks Equity Research
Merck (MRK) steals the limelight at ASCO with a key lung cancer data presentation. Lilly (LLY) gains FDA nod for the lower dose of its rheumatoid arthritis candidate, Olumiant.
Roche Rituxan Label Expanded by FDA for Pemphigus Vulgaris
by Zacks Equity Research
Roche (RHHBY) obtains FDA approval for the label expansion of Rituxan for the treatment of adults with pemphigus vulgaris.
TESARO Collaborates With Roche to Develop Zejula Combination
by Zacks Equity Research
TESARO (TSRO) collaborates with Genentech, a subsidiary of Roche, to develop Zejula in combination with an immune-oncology drug for treating ovarian cancer.
ASCO Ends: Winners & Losers at the Key Cancer Research Event
by Kinjel Shah
The annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago sees cancer data presentations from several drug/biotech companies about the latest developments in treating cancer.
Nektar (NKTR) and Bristol-Myers Present Data on Cancer Study
by Zacks Equity Research
Nektar (NKTR) and Bristol-Myers Squibb announce preliminary data from the ongoing PIVOT phase I/II study evaluating the combination of Nektar's NKTR-214 with Bristol-Myers Squibb's Opdivo.
Celgene Presents Data on CAR T Therapy, Revlimid & Pomalyst
by Zacks Equity Research
Biotech major Celgene presents encouraging data on its oncology drugs Revlimid, Pomalyst along with other experimental therapies at the ASCO.